G6PD and hematopoietic and lymphoid cell neoplasm: In this large cohort of G6PD deficient individuals, carefully matched by multiple factors, we did not find evidence for an association between G6PD deficiency and the overall rate of both solid and hematologic cancers during a mean follow-up of 14.3 years, but the lack of statistical association could be due to the relatively low rate of malignancy (~4%) diagnosed in this relatively young cohort.